Stimulatory autoantibodies to the PDGF receptor: A link to fibrosis in scleroderma and a pathway for novel therapeutic targets

被引:34
作者
Gabrielli, Armando [1 ]
Svegliati, Silvia [1 ]
Moroncini, Gianluca [1 ]
Luchetti, Michele [1 ]
Tonnini, Cecilia [1 ]
Avvedimento, Enrico V. [2 ]
机构
[1] Univ Politecn Marche, Dipartimento Sci Med & Chirurg, Sez Clin Med, I-60020 Ancona, Italy
[2] Univ Naples Federico 2, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol & Cellulare, Naples, Italy
关键词
systemic sclerosis; PDGF; PDGF receptor; ROS; fibroblasts;
D O I
10.1016/j.autrev.2007.02.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic sclerosis (scleroderma) is a complex disease characterized by excessive deposition of collagen and abnormalities of blood vessels. In addition, activation of the immune system is a central feature of scleroderma as shown by mononuclear cell infiltration of the skin, autoantibody production and release of inflammatory cytokines. The pathogenesis of the disease is poorly understood and the molecular events underlying the main clinical features are not known. The detection of agonistic autoantibodies targeting PDGF receptor in serum of patients with scleroderma may indicate a novel link between phenotypic features of the disease and a specific signalling pathway. Agonistic PDGF receptor antibodies induce in vitro the scleroderma phenotype in normal human fibroblasts and, thus, link autoimmunity to fibrosis. These findings pave the way to novel therapeutic strategies. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:121 / 126
页数:6
相关论文
共 39 条
[1]   Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis [J].
Artlett, CM ;
Smith, JB ;
Jimenez, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (17) :1186-1191
[2]   New perspectives on the etiology of systemic sclerosis [J].
Artlett, CM ;
Smith, JB ;
Jimenez, SA .
MOLECULAR MEDICINE TODAY, 1999, 5 (02) :74-78
[3]   B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse [J].
Asano, N ;
Fujimoto, M ;
Yazawa, N ;
Shirasawa, S ;
Hasegawa, M ;
Okochi, H ;
Tamaki, K ;
Tedder, TF ;
Sato, S .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (02) :641-650
[4]  
Baroni SS, 2006, NEW ENGL J MED, V354, P2667
[5]   Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis [J].
Chizzolini, C ;
Raschi, E ;
Rezzonico, R ;
Testoni, C ;
Mallone, R ;
Gabrielli, A ;
Facchini, A ;
Del Papa, N ;
Borghi, MO ;
Dayer, JM ;
Meroni, PL .
ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1602-1613
[6]   SOLUBLE INTERLEUKIN-2 RECEPTORS IN PATIENTS WITH SYSTEMIC-SCLEROSIS - CLINICAL AND LABORATORY CORRELATIONS [J].
DEGIANNIS, D ;
SEIBOLD, JR ;
CZARNECKI, M ;
RASKOVA, J ;
RASKA, K .
ARTHRITIS AND RHEUMATISM, 1990, 33 (03) :375-380
[7]  
DUCAN MR, 1991, J INVEST DERMATOL, V97, P686
[8]   EARLY PHENOTYPIC ACTIVATION OF CIRCULATING HELPER MEMORY T-CELLS IN SCLERODERMA - CORRELATION WITH DISEASE-ACTIVITY [J].
FIOCCO, U ;
ROSADA, M ;
COZZI, L ;
ORTOLANI, C ;
DESILVESTRO, G ;
RUFFATTI, A ;
COZZI, E ;
GALLO, C ;
TODESCO, S .
ANNALS OF THE RHEUMATIC DISEASES, 1993, 52 (04) :272-277
[9]   Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies [J].
Harris, ML ;
Rosen, A .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (06) :778-784
[10]  
Hasegawa M, 1997, J RHEUMATOL, V24, P328